卵巢癌干细胞：新视野
Ovarian Cancer Stem Cells: Newer Horizons.
作者信息
Srivastava Mala, Ahlawat Neha, Srivastava Ankita
机构信息
Institute of Obstetrics and Gynaecology, Sir Ganga Ram Hospital, New Delhi, India.
出版信息
J Obstet Gynaecol India. 2021 Apr;71(2):115-117. doi: 10.1007/s13224-020-01412-7. Epub 2021 Jan 2.
The ovarian cancer is one of the frequent cancers among women being diagnosed after cervical and breast cancer. The CA ovary is dreaded because even after successful treatment of the primary malignancy, the disease comes back and becomes resistant to conventional management. The prognosis in ovarian cancer management is mostly unsatisfactory, maybe because of the presence of ovarian cancer stem cells (OCSC). The hypothesis is that OCSC causes the recurrence of the ovarian malignancy. The OCSC can be identified by the presence of different markers and marker combinations. The assumptions are that CD44+, CD24+, CD117+, CD133+ and ALDH1+ could be the markers of ovarian cancer stem cells. The epithelial ovarian malignancy if proved as a stem cell disease, then it changes the entire management scenarios. Maybe, this will be the first step in managing the ovarian malignancy in the future.
卵巢癌是女性中仅次于宫颈癌和乳腺癌的常见癌症之一。卵巢癌令人恐惧，因为即使原发性恶性肿瘤得到成功治疗，疾病仍会复发并对传统治疗产生耐药性。卵巢癌治疗的预后大多不尽人意，这可能是由于存在卵巢癌干细胞（OCSC）。假说是OCSC导致卵巢恶性肿瘤复发。OCSC可通过不同标志物及标志物组合的存在来识别。推测CD44 +、CD24 +、CD117 +、CD133 +和ALDH1 +可能是卵巢癌干细胞的标志物。如果上皮性卵巢恶性肿瘤被证明是一种干细胞疾病，那么这将改变整个治疗方案。也许，这将是未来治疗卵巢恶性肿瘤的第一步。
Zotero 插件